| Year |
Citation |
Score |
| 2024 |
Conte B, Brasó-Maristany F, Hernández AR, Pascual T, Villacampa G, Schettini F, Vidal Losada MJ, Seguí E, Angelats L, Garcia-Fructuoso I, Gómez-Bravo R, Lorman-Carbó N, Paré L, Marín-Aguilera M, Martínez-Sáez O, ... ... Parker JS, et al. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies. Ebiomedicine. 102: 105043. PMID 38447275 DOI: 10.1016/j.ebiom.2024.105043 |
0.56 |
|
| 2023 |
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley KA, Parker JS, Singh B, Campbell JD, Ballman KV, Hillman DW, Winer EP, El-Abed S, Piccart M, Di Cosimo S, Symmans WF, et al. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications. 14: 7053. PMID 37923752 DOI: 10.1038/s41467-023-42635-2 |
0.708 |
|
| 2023 |
Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 4192-4199. PMID 37672882 DOI: 10.1200/JCO.22.02511 |
0.553 |
|
| 2023 |
Tovey H, Sipos O, Parker JS, Hoadley KA, Quist J, Kernaghan S, Kilburn L, Salgado R, Loi S, Kennedy RD, Roxanis I, Gazinska P, Pinder SE, Bliss J, Perou CM, et al. Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF15. PMID 37574209 DOI: 10.1158/1078-0432.CCR-23-0370 |
0.668 |
|
| 2023 |
Waks AG, Ogayo ER, Paré L, Marín-Aguilera M, Brasó-Maristany F, Galván P, Castillo O, Martínez-Sáez O, Vivancos A, Villagrasa P, Villacampa G, Tarantino P, Desai N, Guerriero J, Metzger O, ... ... Parker JS, et al. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. Jama Oncology. PMID 37103927 DOI: 10.1001/jamaoncol.2023.0181 |
0.524 |
|
| 2023 |
Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Massarrah T, Jerez Y, Ayala de la Peña F, García-Sáenz JÁ, Moreno F, Rodríguez-Lescure Á, Malón-Giménez D, Ballesteros García AI, Marín-Aguilera M, Galván P, ... ... Parker JS, et al. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. Jama Oncology. PMID 37103916 DOI: 10.1001/jamaoncol.2023.0187 |
0.547 |
|
| 2023 |
Prat A, Brasó-Maristany F, Martínez-Sáez O, Sanfeliu E, Xia Y, Bellet M, Galván P, Martínez D, Pascual T, Marín-Aguilera M, Rodríguez A, Chic N, Adamo B, Paré L, Vidal M, ... ... Parker JS, et al. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nature Communications. 14: 1157. PMID 36859416 DOI: 10.1038/s41467-023-36801-9 |
0.583 |
|
| 2023 |
Price BA, Marron JS, Mose LE, Perou CM, Parker JS. Translating transcriptomic findings from cancer model systems to humans through joint dimension reduction. Communications Biology. 6: 179. PMID 36797360 DOI: 10.1038/s42003-023-04529-3 |
0.458 |
|
| 2022 |
Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, ... ... Parker JS, et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer. PMID 36585450 DOI: 10.1038/s43018-022-00491-x |
0.719 |
|
| 2022 |
Brasó-Maristany F, Griguolo G, Chic N, Pascual T, Paré L, Maues J, Galván P, Dieci MV, Miglietta F, Giarratano T, Martínez-Sáez O, Marín-Aguilera M, Schettini F, Conte B, Angelats L, ... ... Parker JS, et al. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. Journal of the National Cancer Institute. PMID 36576009 DOI: 10.1093/jnci/djac227 |
0.488 |
|
| 2022 |
Guarneri V, Bras-Maristany F, Dieci MV, Griguolo G, Par L, Mar Ín-Aguilera M, Miglietta F, Bottosso M, Giorgi CA, Blasco P, Castillo O, Galv N P, Vivancos A, Villagrasa P, Parker JS, et al. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial. Ebiomedicine. 85: 104320. PMID 36374768 DOI: 10.1016/j.ebiom.2022.104320 |
0.563 |
|
| 2022 |
Routh ED, Van Swearingen AED, Sambade MJ, Vensko S, McClure MB, Woodcock MG, Chai S, Cuaboy LA, Wheless A, Garrett A, Carey LA, Hoyle AP, Parker JS, Vincent BG, Anders CK. Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419. Frontiers in Oncology. 12: 818693. PMID 35992833 DOI: 10.3389/fonc.2022.818693 |
0.407 |
|
| 2022 |
Kelly MR, Wisniewska K, Regner MJ, Lewis MW, Perreault AA, Davis ES, Phanstiel DH, Parker JS, Franco HL. A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer. Nature Communications. 13: 4247. PMID 35869079 DOI: 10.1038/s41467-022-31919-8 |
0.351 |
|
| 2022 |
Xia Y, He X, Renshaw L, Martinez-Perez C, Kay C, Gray M, Meehan J, Parker JS, Perou CM, Carey LA, Dixon JM, Turnbull A. Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35653148 DOI: 10.1158/1078-0432.CCR-21-3189 |
0.562 |
|
| 2022 |
Nishijima TF, Kardos J, Chai S, Smith CC, Bortone DS, Selitsky SR, Parker JS, Sanoff HK, Lee MS, Vincent BG. Molecular and Clinical Characterization of a Claudin-Low Subtype of Gastric Cancer. Jco Precision Oncology. 1: 1-10. PMID 35172495 DOI: 10.1200/PO.17.00047 |
0.332 |
|
| 2022 |
Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101506. PMID 35044810 DOI: 10.1200/JCO.21.01506 |
0.649 |
|
| 2022 |
Prat A, Guarneri V, Pascual T, Brasó-Maristany F, Sanfeliu E, Paré L, Schettini F, Martínez D, Jares P, Griguolo G, Dieci MV, Cortés J, Llombart-Cussac A, Conte B, Marín-Aguilera M, ... ... Parker JS, et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. Ebiomedicine. 75: 103801. PMID 34990895 DOI: 10.1016/j.ebiom.2021.103801 |
0.54 |
|
| 2021 |
Bergamino Sirvén MA, Morani G, Parker JS, Schuster EF, Ferreira Leal M, López-Knowles E, Tovey H, Bliss JM, Robertson JF, Smith IE, Dowsett M, Cheang MCU. Impact of duration of neoadjuvant aromatase inhibitors on molecular expression profiles in estrogen receptor positive breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34965950 DOI: 10.1158/1078-0432.CCR-21-2718 |
0.34 |
|
| 2021 |
Regner MJ, Wisniewska K, Garcia-Recio S, Thennavan A, Mendez-Giraldez R, Malladi VS, Hawkins G, Parker JS, Perou CM, Bae-Jump VL, Franco HL. A multi-omic single-cell landscape of human gynecologic malignancies. Molecular Cell. 81: 4924-4941.e10. PMID 34739872 DOI: 10.1016/j.molcel.2021.10.013 |
0.507 |
|
| 2021 |
Little P, Jo H, Hoyle A, Mazul A, Zhao X, Salazar AH, Farquhar D, Sheth S, Masood M, Hayward MC, Parker JS, Hoadley KA, Zevallos J, Hayes DN. UNMASC: tumor-only variant calling with unmatched normal controls. Nar Cancer. 3: zcab040. PMID 34632388 DOI: 10.1093/narcan/zcab040 |
0.541 |
|
| 2021 |
Jariwala N, Mehta GA, Bhatt V, Hussein S, Parker KA, Yunus N, Parker JS, Guo JY, Gatza ML. CPT1A and fatty acid β-oxidation are essential for tumor cell growth and survival in hormone receptor-positive breast cancer. Nar Cancer. 3: zcab035. PMID 34514415 DOI: 10.1093/narcan/zcab035 |
0.414 |
|
| 2021 |
Angus SP, Stuhlmiller TJ, Mehta G, Bevill SM, Goulet DR, Olivares-Quintero JF, East MP, Tanioka M, Zawistowski JS, Singh D, Sciaky N, Chen X, He X, Rashid NU, Chollet-Hinton L, ... ... Parker JS, et al. FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. Npj Breast Cancer. 7: 51. PMID 33980863 DOI: 10.1038/s41523-021-00258-0 |
0.513 |
|
| 2021 |
Morton LM, Karyadi DM, Stewart C, Bogdanova TI, Dawson ET, Steinberg MK, Dai J, Hartley SW, Schonfeld SJ, Sampson JN, Maruvka Y, Kapoor V, Ramsden DA, Carvajal-Garcia J, Perou CM, ... Parker JS, et al. Radiation-related genomic profile of papillary thyroid cancer after the Chernobyl accident. Science (New York, N.Y.). PMID 33888599 DOI: 10.1126/science.abg2538 |
0.379 |
|
| 2021 |
Lou J, Yang Y, Gu Q, Price BA, Qiu Y, Fedoriw Y, Desai S, Mose LE, Chen B, Tateishi S, Parker JS, Vaziri C, Wu D. Rad18 mediates specific mutational signatures and shapes the genomic landscape of carcinogen-induced tumors . Nar Cancer. 3: zcaa037. PMID 33447826 DOI: 10.1093/narcan/zcaa037 |
0.321 |
|
| 2020 |
Kardos J, Rose TL, Manocha U, Wobker SE, Damrauer JS, Bivalaqua TJ, Kates M, Moore KJ, Parker JS, Kim WY. Development and validation of a NanoString BASE47 bladder cancer gene classifier. Plos One. 15: e0243935. PMID 33332422 DOI: 10.1371/journal.pone.0243935 |
0.311 |
|
| 2020 |
Prat A, Guarneri V, Paré L, Griguolo G, Pascual T, Dieci MV, Chic N, González-Farré B, Frassoldati A, Sanfeliu E, Cejalvo JM, Muñoz M, Bisagni G, Brasó-Maristany F, Urso L, ... ... Parker JS, et al. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. The Lancet. Oncology. 21: 1455-1464. PMID 33152285 DOI: 10.1016/S1470-2045(20)30450-2 |
0.527 |
|
| 2020 |
Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, et al. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001276. PMID 33095682 DOI: 10.1200/JCO.20.01276 |
0.655 |
|
| 2020 |
Prat A, Tsai YH, Pascual T, Paré L, Adamo B, Vidal M, Brasó-Maristany F, Galván P, Brase JC, Rodrik-Outmezguine V, Johnston SRD, Ciruelos EM, Parker JS. A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32962980 DOI: 10.1158/1078-0432.CCR-20-2793 |
0.331 |
|
| 2020 |
Innocenti F, Sibley AB, Patil SA, Etheridge AS, Jiang C, Ou FS, Howell S, Plummer SJ, Casey G, Bertagnolli MM, McLeod HL, Auman JT, Blanke CD, Furukawa Y, Venook AP, ... ... Parker JS, et al. Genomic analysis of germline variation associated with survival of colorectal cancer patients treated with chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32958699 DOI: 10.1158/1078-0432.Ccr-20-2021 |
0.372 |
|
| 2020 |
Gorlov IP, Amos CI, Tsavachidis S, Begg C, Hernando E, Cheng C, Shen R, Orlow I, Luo L, Ernstoff MS, Parker J, Thomas NE, Gorlova OY, Berwick M. Human genes differ by their UV sensitivity estimated through analysis of UV-induced silent mutations in melanoma. Human Mutation. PMID 32643855 DOI: 10.1002/Humu.24078 |
0.362 |
|
| 2020 |
Lundberg A, Lindström LS, Parker JS, Löverli E, Perou CM, Bergh J, Tobin NP. A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels. Oncogene. PMID 32581248 DOI: 10.1038/S41388-020-1367-4 |
0.517 |
|
| 2020 |
Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galván P, Fan C, Selitsky SR, Coffey AR, Marron D, Brasó-Maristany F, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. The Journal of Clinical Investigation. PMID 32573490 DOI: 10.1172/Jci130323 |
0.642 |
|
| 2020 |
Fagan-Solis KD, Simpson DA, Kumar RJ, Martelotto LG, Mose LE, Rashid NU, Ho AY, Powell SN, Wen YH, Parker JS, Reis-Filho JS, Petrini JHJ, Gupta GP. A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability. Cell Reports. 30: 1385-1399.e7. PMID 32023457 DOI: 10.1016/J.Celrep.2020.01.020 |
0.415 |
|
| 2020 |
Selitsky SR, Marron D, Hollern D, Mose LE, Hoadley KA, Jones C, Parker JS, Dittmer DP, Perou CM. Virus expression detection reveals RNA-sequencing contamination in TCGA. Bmc Genomics. 21: 79. PMID 31992194 DOI: 10.1186/S12864-020-6483-6 |
0.629 |
|
| 2020 |
Risueno A, Hagner PR, Towfic F, Fontanillo C, Djebbari A, Parker JS, Drew C, Nowakowski GS, Maurer MJ, Cerhan JR, Wei X, Ren Y, Lee CW, Couto S, Wang M, et al. Leveraging Gene Expression Subgroups to Classify DLBCL Patients and Enrich for Clinical Benefit to a Novel Agent. Blood. PMID 31977005 DOI: 10.1182/Blood.2019002414 |
0.412 |
|
| 2020 |
Innocenti F, Selitsky SR, Parker JS, Auman JT, Hammond K, Patil SA, Sanoff HK, Lee MS. Association of KRAS and BRAF mutations with progression-free survival (PFS) with second-line FOLFIRI +/- regorafenib in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 38: 196-196. DOI: 10.1200/Jco.2020.38.4_Suppl.196 |
0.318 |
|
| 2020 |
Tovey H, Parker JS, Hoadley KA, Kennedy RD, Sipos O, Kilburn L, Kernaghan S, Gazinska P, Haider S, Pinder SE, Bliss J, Perou CM, Grigoriadis A, Tutt A, Cheang MCU. Evaluation of DNA repair biology signatures to predict specific carboplatin (C) versus docetaxel (D) benefit in advanced triple-negative breast cancer (aTNBC). Journal of Clinical Oncology. 38: 1074-1074. DOI: 10.1200/Jco.2020.38.15_Suppl.1074 |
0.665 |
|
| 2020 |
Xia Y, Fan C, Hoadley KA, Parker JS, Perou CM. Abstract P4-05-12: Genetic determinants of the molecular portraits of epithelial cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-05-12 |
0.741 |
|
| 2020 |
King TA, Liu MC, McClure MB, Hinoue T, Kelly BJ, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Rezk S, Garrett AL, Balko JM, Parker JS, Park BH, et al. Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs3-08 |
0.748 |
|
| 2020 |
Lee MS, Keku TO, McCoy A, Selitsky SR, Parker J, Auman T, Hammond K, Patil SA, Manyam G, Kopetz S, Sanoff HK, Innocenti F. Abstract A03: Association of Fusobacterium nucleatum (F. nucleatum) with progression-free survival (PFS) and overall survival (OS) with 2nd-line FOLFIRI +/- regorafenib in metastatic colorectal cancer (mCRC) Cancer Research. 80. DOI: 10.1158/1538-7445.Mvc2020-A03 |
0.317 |
|
| 2019 |
Xia Y, Fan C, Hoadley KA, Parker JS, Perou CM. Genetic determinants of the molecular portraits of epithelial cancers. Nature Communications. 10: 5666. PMID 31827079 DOI: 10.1038/S41467-019-13588-2 |
0.732 |
|
| 2019 |
Hollern DP, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott KR, He X, Garay JP, Carey-Ewend K, Marron D, Ford J, Liu S, Vick SC, Martin M, Parker JS, et al. B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell. 179: 1191-1206.e21. PMID 31730857 DOI: 10.1016/J.Cell.2019.10.028 |
0.575 |
|
| 2019 |
Feng W, Simpson DA, Carvajal-Garcia J, Price BA, Kumar RJ, Mose LE, Wood RD, Rashid N, Purvis JE, Parker JS, Ramsden DA, Gupta GP. Genetic determinants of cellular addiction to DNA polymerase theta. Nature Communications. 10: 4286. PMID 31537809 DOI: 10.1038/S41467-019-12234-1 |
0.387 |
|
| 2019 |
Leslie PL, Chao YL, Tsai YH, Ghosh SK, Porrello A, Van Swearingen AED, Harrison EB, Cooley BC, Parker JS, Carey LA, Pecot CV. Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. Nature Communications. 10: 4192. PMID 31519896 DOI: 10.1038/S41467-019-12222-5 |
0.436 |
|
| 2019 |
Smith CC, Chai S, Washington AR, Lee SJ, Landoni E, Field K, Garness J, Bixby LM, Selitsky SR, Parker JS, Savoldo B, Serody JS, Vincent BG. Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. Cancer Immunology Research. PMID 31515258 DOI: 10.1158/2326-6066.Cir-19-0155 |
0.365 |
|
| 2019 |
Barrow MA, Martin ME, Coffey A, Andrews PL, Jones GS, Reaves DK, Parker JS, Troester MA, Fleming JM. A functional role for the cancer disparity-linked genes, CRYβB2 and CRYβB2P1, in the promotion of breast cancer. Breast Cancer Research : Bcr. 21: 105. PMID 31511085 DOI: 10.1186/S13058-019-1191-3 |
0.484 |
|
| 2019 |
Prat A, Parker JS. Standardized versus research-based PAM50 intrinsic subtyping of breast cancer. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. PMID 31435878 DOI: 10.1007/S12094-019-02203-X |
0.445 |
|
| 2019 |
Gao GF, Parker JS, Reynolds SM, Silva TC, Wang LB, Zhou W, Akbani R, Bailey M, Balu S, Berman BP, Brooks D, Chen H, Cherniack AD, Demchok JA, Ding L, et al. Before and After: Comparison of Legacy and Harmonized TCGA Genomic Data Commons' Data. Cell Systems. 9: 24-34.e10. PMID 31344359 DOI: 10.1016/J.Cels.2019.06.006 |
0.577 |
|
| 2019 |
Picornell AC, Echavarria I, Alvarez E, López-Tarruella S, Jerez Y, Hoadley K, Parker JS, Del Monte-Millán M, Ramos-Medina R, Gayarre J, Ocaña I, Cebollero M, Massarrah T, Moreno F, García Saenz JA, et al. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. Bmc Genomics. 20: 452. PMID 31159741 DOI: 10.1186/S12864-019-5849-0 |
0.724 |
|
| 2019 |
Selitsky SR, Mose LE, Smith CC, Chai S, Hoadley KA, Dittmer DP, Moschos SJ, Parker JS, Vincent BG. Prognostic value of B cells in cutaneous melanoma. Genome Medicine. 11: 36. PMID 31138334 DOI: 10.1186/S13073-019-0647-5 |
0.584 |
|
| 2019 |
Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, ... ... Parker JS, et al. HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. Journal of the National Cancer Institute. PMID 31037288 DOI: 10.1093/Jnci/Djz042 |
0.476 |
|
| 2019 |
Vora NL, Parker JS, Mieckowski PA, Smeester L, Fry RC, Boggess KA. RNA-Sequencing of Umbilical Cord Blood to Investigate Spontaneous Preterm Birth: A Pilot Study. Ajp Reports. 9: e60-e66. PMID 30854245 DOI: 10.1055/S-0039-1678717 |
0.319 |
|
| 2019 |
Wong KY, Fan C, Tanioka M, Parker JS, Nobel AB, Zeng D, Lin DY, Perou CM. I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms. Genome Biology. 20: 52. PMID 30845957 DOI: 10.1186/S13059-019-1640-4 |
0.523 |
|
| 2019 |
Alzubi MA, Turner TH, Olex AL, Sohal SS, Tobin NP, Recio SG, Bergh J, Hatschek T, Parker JS, Sartorius CA, Perou CM, Dozmorov MG, Harrell JC. Separation of breast cancer and organ microenvironment transcriptomes in metastases. Breast Cancer Research : Bcr. 21: 36. PMID 30841919 DOI: 10.1186/S13058-019-1123-2 |
0.54 |
|
| 2019 |
Mose LE, Perou CM, Parker JS. Improved Indel Detection in DNA and RNA via Realignment with ABRA2. Bioinformatics (Oxford, England). PMID 30649250 DOI: 10.1093/Bioinformatics/Btz033 |
0.483 |
|
| 2019 |
Lee MS, Selitsky SR, Parker JS, Auman JT, Wu Y, Hammond K, O'Neil B, Sanoff HK, Innocenti F. Association of consensus molecular subtypes (CMS) with time to progression (TTP), progression free survival (PFS), and overall survival (OS) with second-line FOLFIRI ± regorafenib in metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 37: 597-597. DOI: 10.1200/Jco.2019.37.4_Suppl.597 |
0.322 |
|
| 2019 |
Beaty BT, Gupta G, Shen CJ, Amdur RJ, Weiss J, Grilley-Olson JE, Patel SA, Zanation AM, Hackman T, Thorp B, Blumberg J, Patel S, Weissler MC, Yarbrough WG, Sheets NC, ... Parker JS, et al. PIK3CA mutation as a prognostic factor in HPV-associated oropharynx cancer. Journal of Clinical Oncology. 37: 6011-6011. DOI: 10.1200/Jco.2019.37.15_Suppl.6011 |
0.32 |
|
| 2019 |
Fernandez-Martinez A, Tanioka M, Fan C, Parker JS, Hoadley KA, Krop IE, Cortes J, Llombart Cussac A, Nuciforo P, Galván P, Pascual T, Partridge AH, Prat A, Carey LA, Perou CM. Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials. Journal of Clinical Oncology. 37: 571-571. DOI: 10.1200/Jco.2019.37.15_Suppl.571 |
0.702 |
|
| 2019 |
Hollern D, Xu N, Mott K, He X, Carey-Ewend K, Marron D, Ford J, Parker J, Vincent B, Serody J, Perou C. Abstract GS1-05: Apobec3 induced mutagenesis sensitizes murine models of triple negative breast cancer to immunotherapy by activating B-cells and CD4+ T-cells Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Gs1-05 |
0.588 |
|
| 2019 |
Mose LE, Marron D, Parker JS. Abstract 1678: Accurate detection of expressed variation in RNA-seq Cancer Research. 79: 1678-1678. DOI: 10.1158/1538-7445.Sabcs18-1678 |
0.445 |
|
| 2019 |
Vincent B, Sambade M, Chai S, Siegel M, Cuaboy L, Holye A, Parker J, Perou C, Anders C. THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES Neuro-Oncology Advances. 1: i11-i12. DOI: 10.1093/NOAJNL/VDZ014.049 |
0.55 |
|
| 2019 |
Fernandez-Martinez A, Tanioka M, Fan C, Parker JS, Hoadley KA, Krop I, Partridge A, Carey L, Perou CM. Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer : A correlative analysis of the CALGB 40601 clinical trial (Alliance) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz240 |
0.734 |
|
| 2019 |
Prat A, Tsai Y-, Pascual T, Paré L, Vidal M, Adamo B, Brase JC, Johnston SRD, Ciruelos EM, Parker JS. PAM50MET: A prognostic model based on PAM50 and clinical variables in metastatic hormone receptor (HR)-positive/HER2 negative breast cancer. Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz095.006 |
0.45 |
|
| 2018 |
Bianchini G, Parker J, Carey L, Perou CM, Sica L, Prat A, Pieńkowski T, Im YH, Bianchi GV, Ling-Ming T, Liu MC, Lluch A, Semiglazov V, de la Haba-Rodriguez J, Oh DY, et al. Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii61. PMID 32137631 DOI: 10.1093/Annonc/Mdy270.187 |
0.432 |
|
| 2018 |
Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, et al. The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Frontiers in Oncology. 8: 584. PMID 30662871 DOI: 10.3389/Fonc.2018.00584 |
0.602 |
|
| 2018 |
Kensler KH, Sankar VN, Wang J, Zhang X, Rubadue CA, Baker GM, Parker JS, Hoadley KA, Stancu AL, Pyle ME, Collins LC, Hunter DJ, Elissen AH, Hankinson SE, Tamimi RM, et al. PAM50 Molecular Intrinsic Subtypes in the Nurses' Health Study Cohorts. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30591591 DOI: 10.1158/1055-9965.Epi-18-0863 |
0.608 |
|
| 2018 |
Cai L, Tsai YH, Wang P, Wang J, Li D, Fan H, Zhao Y, Bareja R, Lu R, Wilson EM, Sboner A, Whang YE, Zheng D, Parker JS, Earp HS, et al. ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Molecular Cell. PMID 30270106 DOI: 10.1016/J.Molcel.2018.08.029 |
0.319 |
|
| 2018 |
Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Research and Treatment. PMID 30267249 DOI: 10.1007/S10549-018-4921-9 |
0.427 |
|
| 2018 |
Smith CC, Beckermann KE, Bortone DS, de Cubas AA, Bixby LM, Lee SJ, Panda A, Ganesan S, Bhanot G, Wallen EM, Milowsky MI, Kim WY, Rathmell WK, Swanstrom R, Parker JS, et al. Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. The Journal of Clinical Investigation. PMID 30137025 DOI: 10.1172/Jci121476 |
0.445 |
|
| 2018 |
Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry NL, Tolaney S, Dang CT, Krop I, Harris LN, et al. Integrated analysis of RNA and DNA from a phase III trial of trastuzumab-based neoadjuvant chemotherapy identifies response predictors in HER2-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30037817 DOI: 10.1158/1078-0432.Ccr-17-3431 |
0.704 |
|
| 2018 |
Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, ... ... Parker JS, et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science (New York, N.Y.). 361: 290-295. PMID 30026228 DOI: 10.1126/Science.Aap8411 |
0.489 |
|
| 2018 |
Desai NV, Torous V, Parker J, Auman JT, Rosson GB, Cruz C, Perou CM, Schnitt SJ, Tung N. Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay. Breast Cancer Research : Bcr. 20: 75. PMID 29996866 DOI: 10.1186/S13058-018-1005-Z |
0.571 |
|
| 2018 |
Gorlov I, Orlow I, Ringelberg C, Hernando E, Ernstoff MS, Cheng C, Her S, Parker JS, Thompson CL, Gerstenblith MR, Berwick M, Amos C. Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics. Melanoma Research. PMID 29975213 DOI: 10.1097/Cmr.0000000000000473 |
0.404 |
|
| 2018 |
Van Swearingen AED, Siegel MB, Deal AM, Sambade MJ, Hoyle A, Hayes DN, Jo H, Little P, Dees EC, Muss H, Jolly T, Zagar TM, Patel N, Miller CR, Parker JS, et al. LCCC 1025: a phase II study of everolimus, trastuzumab, and vinorelbine to treat progressive HER2-positive breast cancer brain metastases. Breast Cancer Research and Treatment. PMID 29938395 DOI: 10.1007/S10549-018-4852-5 |
0.412 |
|
| 2018 |
Bensen JT, Graff M, Young KL, Sethupathy P, Parker J, Pecot CV, Currin K, Haddad SA, Ruiz-Narváez EA, Haiman CA, Hong CC, Sucheston-Campbell LE, Zhu Q, Liu S, Yao S, et al. A survey of microRNA single nucleotide polymorphisms identifies novel breast cancer susceptibility loci in a case-control, population-based study of African-American women. Breast Cancer Research : Bcr. 20: 45. PMID 29871690 DOI: 10.1186/S13058-018-0964-4 |
0.349 |
|
| 2018 |
Coombs CC, Gillis NK, Tan X, Berg JS, Ball MC, Balasis ME, Montgomery ND, Bolton K, Parker JS, Mesa TE, Yoder SJ, Hayward MC, Patel NM, Richards KL, Walko CM, et al. Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired next-generation sequencing assays. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29866652 DOI: 10.1158/1078-0432.Ccr-18-1201 |
0.326 |
|
| 2018 |
Chiang YC, Park IY, Terzo EA, Tripathi DN, Mason FM, Fahey CC, Karki M, Shuster CB, Sohn BH, Chowdhury P, Powell RT, Ohi R, Tsai YH, de Cubas AA, Khan A, ... ... Parker JS, et al. SETD2 Haploinsufficiency for Microtubule Methylation is an Early Driver of Genomic Instability in Renal Cell Carcinoma. Cancer Research. PMID 29724720 DOI: 10.1158/0008-5472.Can-17-3460 |
0.307 |
|
| 2018 |
Tsai YH, Parker JS, Yang IV, Kelada SNP. Meta-Analysis of Airway Epithelia Gene Expression in Asthma. The European Respiratory Journal. PMID 29650561 DOI: 10.1183/13993003.01962-2017 |
0.311 |
|
| 2018 |
Dellon ES, Selitsky SR, Genta RM, Lash RH, Parker JS. Gene expression-phenotype associations in adults with eosinophilic esophagitis. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association For the Study of the Liver. PMID 29628359 DOI: 10.1016/J.Dld.2018.03.021 |
0.324 |
|
| 2018 |
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, ... ... Parker JS, et al. The Immune Landscape of Cancer. Immunity. PMID 29628290 DOI: 10.1016/J.Immuni.2018.03.023 |
0.424 |
|
| 2018 |
Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, ... ... Parker JS, et al. Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. The Journal of Clinical Investigation. PMID 29480819 DOI: 10.1172/Jci96153 |
0.733 |
|
| 2018 |
Montgomery ND, Selitsky SR, Patel NM, Hayes DN, Parker JS, Weck KE. Identification of Germline Variants in Tumor Genomic Sequencing Analysis. The Journal of Molecular Diagnostics : Jmd. 20: 123-125. PMID 29249243 DOI: 10.1016/J.Jmoldx.2017.09.008 |
0.343 |
|
| 2018 |
Coombs CC, Gillis N, Bolton KL, Berg JS, Tan X, Hayward MC, Patel NM, Ball M, Balasis M, Mesa T, Montgomery N, Richards KL, Kim WY, Hayes DN, Earp S, ... Parker JS, et al. Identification of clonal hematopoiesis mutations in solid tumor patients undergoing unpaired commercial next-generation sequencing assays. Journal of Clinical Oncology. 36: 12068-12068. DOI: 10.1200/Jco.2018.36.15_Suppl.12068 |
0.327 |
|
| 2018 |
Zeidner JF, Vincent BG, Ivanova A, Foster MC, Coombs CC, Jamieson K, Van Deventer HW, Blanchard L, Frank C, Gallagher S, Matson M, Pepin K, Vaught L, Vogler N, Miller K, ... ... Parker JS, et al. Genomics Reveal Potential Biomarkers of Response to Pembrolizumab after High Dose Cytarabine in an Ongoing Phase II Trial in Relapsed/Refractory AML Blood. 132: 4054-4054. DOI: 10.1182/Blood-2018-99-116608 |
0.322 |
|
| 2018 |
Dixon J, Turnbull A, Tanioka M, Wheless A, Garrett A, Martinez-Perez C, Parker J, He X, Sims A, Thomas J, Carey L, Perou C. Abstract P4-03-01: Causes of endocrine therapy resistance: An in-depth genomic analysis of resistant multidrug ER+ breast cancers Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-03-01 |
0.364 |
|
| 2018 |
Vincent BG, Sambade M, Chai S, Siegel MB, Cuaboy L, Hoyle A, Parker J, Perou CM, Anders CK. Abstract 4055: Genomic and immune characterization of triple-negative breast cancer brain metastases Cancer Research. 78: 4055-4055. DOI: 10.1158/1538-7445.Am2018-4055 |
0.6 |
|
| 2018 |
Bowers LW, McDonell SB, Rossi E, Montgomery S, Parker J, Hursting SD. Abstract 2233: Breaking the obesity-cancer link: Nutritional modulation of inflammation and epigenetic reprogramming Cancer Research. 78: 2233-2233. DOI: 10.1158/1538-7445.Am2018-2233 |
0.343 |
|
| 2018 |
Tanioka M, Parker JS, Henry LN, Tolaney S, Dang C, Krop IE, Harris L, Hillman D, Polley M, Berry DA, Winer EP, Carey LA, Perou CM. A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance) Annals of Oncology. 29: vii50. DOI: 10.1093/Annonc/Mdy373 |
0.469 |
|
| 2018 |
Dellon ES, Bodwin K, He M, Parker JS, Nobel AB, Selitsky SR. 461 - Pre-Tretment Differential Correlaton of Gene Expression, Rather than Differential Expression, is Associated with Subsequent Response to Topcial Steroid Treatment in Eosinophilic Esophagitis Gastroenterology. 154: S-107. DOI: 10.1016/S0016-5085(18)30795-9 |
0.311 |
|
| 2018 |
Gupta G, Kumar S, Marron D, Amdur R, Hayes D, Weiss J, Grilley-Olson J, Zanation A, Hackman T, Zevallos J, Patel S, Weissler M, Parker J, Mendenhall W, Chera B. Circulating Tumor HPV16 DNA as a Biomarker of Tumor Genomics and Disease Control in HPV-associated Oropharyngeal Squamous Cell Carcinoma International Journal of Radiation Oncology*Biology*Physics. 100: 1310-1311. DOI: 10.1016/J.Ijrobp.2017.12.291 |
0.301 |
|
| 2017 |
Patel NM, Michelini VV, Snell JM, Balu S, Hoyle AP, Parker JS, Hayward MC, Eberhard DA, Salazar AH, McNeillie P, Xu J, Huettner CS, Koyama T, Utro F, Rhrissorrakrai K, et al. Enhancing Next-Generation Sequencing-Guided Cancer Care Through Cognitive Computing. The Oncologist. PMID 29158372 DOI: 10.1634/Theoncologist.2017-0170 |
0.359 |
|
| 2017 |
Liu W, Snell JM, Jeck WR, Hoadley KA, Wilkerson MD, Parker JS, Patel N, Mlombe YB, Mulima G, Liomba NG, Wolf LL, Shores CG, Gopal S, Sharpless NE. Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. Jci Insight. 2. PMID 29148985 DOI: 10.1172/jci.insight.98457 |
0.46 |
|
| 2017 |
Brady SW, McQuerry JA, Qiao Y, Piccolo SR, Shrestha G, Jenkins DF, Layer RM, Pedersen BS, Miller RH, Esch A, Selitsky SR, Parker JS, Anderson LA, Dalley BK, Factor RE, et al. Combating subclonal evolution of resistant cancer phenotypes. Nature Communications. 8: 1231. PMID 29093439 DOI: 10.1038/S41467-017-01174-3 |
0.44 |
|
| 2017 |
Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, Reisdorf S, Anders CK, Carey LA, Parker JS, Perou CM, Vincent BG, Serody JS. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. The Journal of Clinical Investigation. PMID 28825599 DOI: 10.1172/Jci90499 |
0.592 |
|
| 2017 |
O'Flanagan CH, Rossi EL, McDonell SB, Chen X, Tsai YH, Parker JS, Usary J, Perou CM, Hursting SD. Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer. Npj Breast Cancer. 3: 26. PMID 28748213 DOI: 10.1038/s41523-017-0027-5 |
0.528 |
|
| 2017 |
Bailey ST, Smith AM, Kardos J, Wobker SE, Wilson HL, Krishnan B, Saito R, Lee HJ, Zhang J, Eaton SC, Williams LA, Manocha U, Peters DJ, Pan X, Carroll TJ, ... ... Parker JS, et al. MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. Nature Communications. 8: 15770. PMID 28593993 DOI: 10.1038/Ncomms15770 |
0.315 |
|
| 2017 |
Chang J, Tan W, Ling Z, Xi R, Shao M, Chen M, Luo Y, Zhao Y, Liu Y, Huang X, Xia Y, Hu J, Parker JS, Marron D, Cui Q, et al. Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nature Communications. 8: 15290. PMID 28548104 DOI: 10.1038/Ncomms15290 |
0.36 |
|
| 2017 |
Prat A, Navarro A, Paré L, Reguart N, Galvan P, Pascual T, Martínez A, Nuciforo P, Comerma L, Alos L, Pardo N, Cedrés S, Fan C, Parker JS, Gaba L, et al. Immune-related gene expression profiling after PD-1 blockade in non-small cell lung carcinoma, head and neck squamous cell carcinoma and melanoma. Cancer Research. PMID 28487385 DOI: 10.1158/0008-5472.Can-16-3556 |
0.328 |
|
| 2017 |
Van Swearingen AED, Sambade MJ, Siegel MB, Sud S, McNeill RS, Bevill SM, Chen X, Bash RE, Mounsey L, Golitz BT, Santos C, Deal A, Parker JS, Rashid N, Miller CR, et al. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer. Neuro-Oncology. PMID 28486691 DOI: 10.1093/Neuonc/Nox052 |
0.384 |
|
| 2017 |
Silva GO, Siegel MB, Mose LE, Parker JS, Sun W, Perou CM, Chen M. SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling. Genome Biology. 18: 66. PMID 28390427 DOI: 10.1186/S13059-017-1193-3 |
0.492 |
|
| 2017 |
Mehta GA, Parker JS, Silva GO, Hoadley KA, Perou CM, Gatza ML. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Research and Treatment. PMID 28176176 DOI: 10.1007/S10549-017-4139-2 |
0.723 |
|
| 2017 |
Bagó JR, Okolie O, Dumitru R, Ewend MG, Parker JS, Werff RV, Underhill TM, Schmid RS, Miller CR, Hingtgen SD. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Science Translational Medicine. 9. PMID 28148846 DOI: 10.1126/Scitranslmed.Aah6510 |
0.347 |
|
| 2017 |
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, et al. Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex. Cancer Discovery. PMID 28108460 DOI: 10.1158/2159-8290.Cd-16-0653 |
0.525 |
|
| 2017 |
Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER. Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Plos Medicine. 14: e1002222. PMID 28068332 DOI: 10.1371/journal.pmed.1002222 |
0.684 |
|
| 2017 |
Nishijima TF, Kardos J, Chai S, Smith CC, Bortone DS, Mose LE, Selitsky SR, Sanoff HK, Parker JS, Lee MS, Vincent BG. Molecular and clinical characterization of a claudin (CLDN)-low subtype of gastric cancer (GC). Journal of Clinical Oncology. 35: 67-67. DOI: 10.1200/Jco.2017.35.4_Suppl.67 |
0.487 |
|
| 2017 |
Lee MS, Selitsky SR, Parker JS. Prognostic impact of cytomegalovirus (CMV) detection in colorectal cancer (CRC). Journal of Clinical Oncology. 35: e15120-e15120. DOI: 10.1200/Jco.2017.35.15_Suppl.E15120 |
0.38 |
|
| 2017 |
Swearingen AEDV, Sambade MJ, Siegel MB, Sud S, Bevill SM, Golitz BT, Bash RE, Santos CM, Darr DB, Parker JS, Miller CR, Johnson GL, Anders CK. Abstract A03: Several rational combination kinase inhibitor treatments identified by synthetic lethality screens are efficacious in intracranial triple negative breast cancer models Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-A03 |
0.399 |
|
| 2017 |
Vick SC, Taylor NA, Iglesia MD, Brickey WJ, Carey LA, Midkiff BR, McKinnon KP, Reisdorf S, Parker JS, Perou CM, Vincent BG, Serody JS. Abstract 568: Regulatory T cell recruitment limits the effectiveness of checkpoint inhibition for claudin-low breast cancer Immunology. 77: 568-568. DOI: 10.1158/1538-7445.Am2017-568 |
0.564 |
|
| 2017 |
Mose LE, Hayes DN, Perou CM, Parker JS. Abstract 3592: Improved indel detection in RNA-seq data via assembly based re-alignment reveals expressed Epidermal Growth Factor Receptor indels in Lung Adenocarcinoma Cancer Research. 77: 3592-3592. DOI: 10.1158/1538-7445.Am2017-3592 |
0.453 |
|
| 2017 |
Little P, Hayes DN, Parker J, Zevallos J. Abstract 3584: Statistical considerations in tumor only variant calling Cancer Research. 77: 3584-3584. DOI: 10.1158/1538-7445.Am2017-3584 |
0.372 |
|
| 2017 |
Recio SG, Fan C, Siegel M, Parker JS, Duronio GN, Prat A, Perou CM. Abstract 3119: Identification of genetic drivers in HER2enriched/HER2negative breast cancer Cancer Research. 77: 3119-3119. DOI: 10.1158/1538-7445.Am2017-3119 |
0.662 |
|
| 2017 |
Picornell A, Echavarria Diaz-Guardamino I, Alvarez Castillo E, Lopez-Tarruella Cobo S, Jerez Y, Hoadley K, Parker J, del Monte-Millán M, Ramos Medina R, Gayarre J, Ocaña I, Cebollero M, Massarrah T, Moreno Antón F, García-Saenz J, et al. Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms Annals of Oncology. 28: v56-v57. DOI: 10.1093/Annonc/Mdx362.036 |
0.714 |
|
| 2016 |
Snowden E, Porter W, Hahn F, Ferguson M, Tong F, Parker JS, Middlebrook A, Ghanekar S, Dillmore WS, Blaesius R. Immunophenotyping and Transcriptomic Outcomes in PDX-derived TNBC Tissue. Molecular Cancer Research : McR. PMID 28039356 DOI: 10.1158/1541-7786.Mcr-16-0286-T |
0.436 |
|
| 2016 |
Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER. Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Plos Medicine. 13: e1002174. PMID 27923045 DOI: 10.1371/Journal.Pmed.1002174 |
0.7 |
|
| 2016 |
Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, de la Haba-Rodríguez J, Arcusa A, Chacón I, Sánchez-Rovira P, Plazaola A, Muñoz M, Paré L, Parker JS, Ribelles N, et al. A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27903675 DOI: 10.1158/1078-0432.Ccr-16-2092 |
0.589 |
|
| 2016 |
Liu W, Snell JM, Jeck WR, Hoadley KA, Wilkerson MD, Parker JS, Patel N, Mlombe YB, Mulima G, Liomba NG, Wolf LL, Shores CG, Gopal S, Sharpless NE. Subtyping sub-Saharan esophageal squamous cell carcinoma by comprehensive molecular analysis. Jci Insight. 1: e88755. PMID 27734031 DOI: 10.1172/Jci.Insight.88755 |
0.601 |
|
| 2016 |
Kardos J, Chai S, Mose LE, Selitsky SR, Krishnan B, Saito R, Iglesia MD, Milowsky MI, Parker JS, Kim WY, Vincent BG. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. Jci Insight. 1: e85902. PMID 27699256 DOI: 10.1172/Jci.Insight.85902 |
0.458 |
|
| 2016 |
Mose LE, Selitsky SR, Bixby LM, Marron DL, Iglesia MD, Serody JS, Perou CM, Vincent BG, Parker JS. Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V'DJer. Bioinformatics (Oxford, England). PMID 27559159 DOI: 10.1093/Bioinformatics/Btw526 |
0.475 |
|
| 2016 |
Hu S, Parker J, Divaris K, Padilla R, Murrah V, Wright JT. Ameloblastoma Phenotypes Reflected in Distinct Transcriptome Profiles. Scientific Reports. 6: 30867. PMID 27491308 DOI: 10.1038/Srep30867 |
0.332 |
|
| 2016 |
Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. Journal of the National Cancer Institute. 108. PMID 27335052 DOI: 10.1093/Jnci/Djw144 |
0.65 |
|
| 2016 |
Souroullas GP, Jeck WR, Parker JS, Simon JM, Liu JY, Paulk J, Xiong J, Clark KS, Fedoriw Y, Qi J, Burd CE, Bradner JE, Sharpless NE. An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nature Medicine. PMID 27135738 DOI: 10.1038/Nm.4092 |
0.34 |
|
| 2016 |
Seifert BA, O'Daniel JM, Amin K, Marchuk DS, Patel NM, Parker JS, Hoyle AP, Mose LE, Marron A, Hayward MC, Bizon C, Wilhelmsen KC, Evans JP, Earp HS, Sharpless N, et al. Germline Analysis from Tumor-Germline Sequencing Dyads to identify clinically actionable secondary findings. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27083775 DOI: 10.1158/1078-0432.Ccr-16-0015 |
0.453 |
|
| 2016 |
Hu S, Divaris K, Parker J, Padilla R, Murrah V, Wright JT. Transcriptome Variability in Keratocystic Odontogenic Tumor Suggests Distinct Molecular Subtypes. Scientific Reports. 6: 24236. PMID 27066764 DOI: 10.1038/Srep24236 |
0.387 |
|
| 2016 |
Billard MJ, Fitzhugh DJ, Parker JS, Brozowski JM, McGinnis MW, Timoshchenko RG, Serafin DS, Lininger R, Klauber-Demore N, Sahagian G, Truong YK, Sassano MF, Serody JS, Tarrant TK. G Protein Coupled Receptor Kinase 3 Regulates Breast Cancer Migration, Invasion, and Metastasis. Plos One. 11: e0152856. PMID 27049755 DOI: 10.1371/Journal.Pone.0152856 |
0.505 |
|
| 2016 |
López-Knowles E, Gao Q, Cheang MC, Morden J, Parker J, Martin LA, Pinhel I, McNeill F, Hills M, Detre S, Afentakis M, Zabaglo L, Dodson A, Skene A, Holcombe C, et al. Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas. Breast Cancer Research : Bcr. 18: 39. PMID 27036195 DOI: 10.1186/S13058-016-0696-2 |
0.456 |
|
| 2016 |
Zhao W, Hoadley KA, Parker JS, Perou CM. Identification of mRNA isoform switching in breast cancer. Bmc Genomics. 17: 181. PMID 26939613 DOI: 10.1186/S12864-016-2521-9 |
0.719 |
|
| 2016 |
Brooks SA, Khandani A, Fielding J, Lin W, Sills T, Lee Y, Arreola A, Milowsky MI, Wallen EM, Woods ME, Smith AB, Nielsen ME, Parker JS, Lalush DS, Rathmell WK. Alternate metabolic programs define regional variation of relevant biological features in renal cell carcinoma progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26787754 DOI: 10.1158/1078-0432.Ccr-15-2115 |
0.358 |
|
| 2016 |
Grilley-Olsen J, Keith K, Hayward M, Dees E, Deal A, Ivanova A, Benbow J, Parker J, Patel N, Eberhard D, Mieczkowski P, Weck K, Hayes D, Muss H, Jolly T, et al. Abstract PD6-07: Genomic sequencing in metastatic breast cancer patients to inform clinical practice at the University of North Carolina at Chapel Hill Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd6-07 |
0.445 |
|
| 2016 |
Olayiwola O, Ogundiran T, Hardeman A, Yoshimatsu T, Clayton W, Adeoye A, Ademola A, Ajani M, Khramtsova G, Grushko T, Huo D, Zheng Y, Parker J, Perou C, Olopade O. Abstract P6-04-05: Genotype-phenotype classification of triple negative breast cancers (TNBC) in women of African descent using the PAM50 NanoString platform and genomic data Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P6-04-05 |
0.516 |
|
| 2016 |
Miller K, Krop I, Schwartzberg L, Abramson V, Garcia-Estevez L, Eakle J, Nanda R, Yardley D, Ademuyiwa F, Chan S, Crown J, Danso M, Gelmon K, Ma L, Martinez-Janez N, ... ... Parker J, et al. Abstract P3-07-25: Improved clinical outcomes on enzalutamide observed in patients with PREDICT AR+ triple-negative breast cancer: prognosis or prediction? Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-07-25 |
0.359 |
|
| 2016 |
Phan V, Protter A, Peterson A, Parker J, Yoon K, Tudor I, Paton V, Noonberg S, Uppal H. Abstract P2-07-04: A novel diagnostic androgen receptor gene signature links clinical outcomes and preclinical response to enzalutamide, paclitaxel or the combination in triple-negative breast cancer Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P2-07-04 |
0.454 |
|
| 2016 |
Vincent BG, Kim W, Kardos J, Chai S, Parker J, Mose L, Selitsky S, Iglesia M, Milowsky M. Abstract 5120: The novel claudin-low molecular subtype of high-grade urothelial bladder cancer is highly immunogenic yet immunosuppressed Cancer Research. 76: 5120-5120. DOI: 10.1158/1538-7445.Am2016-5120 |
0.511 |
|
| 2016 |
Lee W, Jo H, Yin X, Eberhard DA, Patel NM, Hayward MC, Salazar AH, Parker JS, Kim WY, Earp HS, Sharpless NE, Hayes DN. Abstract 4499: Integration of targeted RNA sequencing to targeted DNA sequencing for the characterization of clinically relevant variants in a population of thousands of patients treated on clinical trial Cancer Research. 76: 4499-4499. DOI: 10.1158/1538-7445.Am2016-4499 |
0.401 |
|
| 2016 |
Porter W, Hahn F, Snowden E, Ferguson M, Tong F, Dillmore S, Parker JS, Middlebrook A, Ghanekar S, Blaesius R. Abstract 2391: Flow cytometric sorting of subpopulations followed by RNASeq reveals distinct phenotypes in PDX model of basal breast cancer Cancer Research. 76: 2391-2391. DOI: 10.1158/1538-7445.Am2016-2391 |
0.475 |
|
| 2015 |
Gendoo DM, Ratanasirigulchai N, Schröder MS, Paré L, Parker JS, Prat A, Haibe-Kains B. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer. Bioinformatics (Oxford, England). PMID 26607490 DOI: 10.1093/Bioinformatics/Btv693 |
0.476 |
|
| 2015 |
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, ... ... Parker JS, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. The New England Journal of Medicine. PMID 26536169 DOI: 10.1056/Nejmoa1505917 |
0.616 |
|
| 2015 |
Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, ... ... Parker JS, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. Bmc Medical Genomics. 8: 54. PMID 26297356 DOI: 10.1186/S12920-015-0129-6 |
0.615 |
|
| 2015 |
Parker JS, Perou CM. Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest? Cancer Cell. 28: 149-50. PMID 26267531 DOI: 10.1016/J.Ccell.2015.07.011 |
0.551 |
|
| 2015 |
Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, Moulder SL, Marcom PK, Ma J, Rosen JM, Perou CM. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Research and Treatment. PMID 26109346 DOI: 10.1007/S10549-015-3476-2 |
0.64 |
|
| 2015 |
Zhao X, Wang A, Walter V, Patel NM, Eberhard DA, Hayward MC, Salazar AH, Jo H, Soloway MG, Wilkerson MD, Parker JS, Yin X, Zhang G, Siegel MB, Rosson GB, et al. Combined Targeted DNA Sequencing in Non-Small Cell Lung Cancer (NSCLC) Using UNCseq and NGScopy, and RNA Sequencing Using UNCqeR for the Detection of Genetic Aberrations in NSCLC. Plos One. 10: e0129280. PMID 26076459 DOI: 10.1371/Journal.Pone.0129280 |
0.406 |
|
| 2015 |
Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, ... ... Parker JS, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. 372: 2481-98. PMID 26061751 DOI: 10.1056/Nejmoa1402121 |
0.611 |
|
| 2015 |
Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, ... ... Parker J, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. The Oncologist. 20: 474-82. PMID 25908555 DOI: 10.1634/Theoncologist.2014-0372 |
0.595 |
|
| 2015 |
Stuhlmiller TJ, Miller SM, Zawistowski JS, Nakamura K, Beltran AS, Duncan JS, Angus SP, Collins KA, Granger DA, Reuther RA, Graves LM, Gomez SM, Kuan PF, Parker JS, Chen X, et al. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains. Cell Reports. 11: 390-404. PMID 25865888 DOI: 10.1016/J.Celrep.2015.03.037 |
0.308 |
|
| 2015 |
Hu S, Parker J, Wright JT. Towards unraveling the human tooth transcriptome: the dentome. Plos One. 10: e0124801. PMID 25849153 DOI: 10.1371/Journal.Pone.0124801 |
0.348 |
|
| 2015 |
Karginova O, Siegel MB, Van Swearingen AE, Deal AM, Adamo B, Sambade MJ, Bazyar S, Nikolaishvili-Feinberg N, Bash R, O'Neal S, Sandison K, Parker JS, Santos C, Darr D, Zamboni W, et al. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 14: 920-30. PMID 25824335 DOI: 10.1158/1535-7163.Mct-14-0474 |
0.454 |
|
| 2015 |
Ferguson J, McKibben M, Parker JS, Wallen E, Wood CG, Powles T, Rathmell K. Evaluation of the effects of neoadjuvant pazopanib for renal cell carcinoma on intratumor genetic heterogeneity. Journal of Clinical Oncology. 33: 425-425. DOI: 10.1200/Jco.2015.33.7_Suppl.425 |
0.355 |
|
| 2015 |
Parker JS, Peterson AC, Tudor IC, Hoffman J, Uppal H. A novel biomarker to predict sensitivity to enzalutamide (ENZA) in TNBC. Journal of Clinical Oncology. 33: 1083-1083. DOI: 10.1200/Jco.2015.33.15_Suppl.1083 |
0.318 |
|
| 2015 |
Hoadley KA, Barry WT, Pitcher BN, Parker JS, Wilkerson MD, Irvin W, Henry NL, Tolaney SM, Dang C, Krop IE, Berry DA, Mardis ER, Perou CM, Winer EP, Hudis CA, et al. Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S3-06 |
0.713 |
|
| 2015 |
Dixon JM, Turnbull AK, Fan C, Parker JS, He X, Arthur L, Martinez-Perez C, Renshaw L, Perou C. Abstract S1-05: In-depth genomic analysis of ER+ breast cancers during development of endocrine resistance Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S1-05 |
0.62 |
|
| 2015 |
Hayes DN, Grilley-Olson JE, Eberhard DA, Patel NM, Parker JS, Weck KE, Kim WY, Hayward MC, Earp HS, Sharpless NE. Abstract CT133: The impact of gene panel sequencing on clinical care in patients with cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct133 |
0.416 |
|
| 2015 |
Swearingen AEDV, Siegel MB, Sambade MJ, Sud S, Miller SM, Silva G, Bash RE, Santos CM, Darr DB, Golitz B, Parker JS, Miller CR, Johnson GL, Anders CK. Abstract 2579: Combination therapy with MEK inhibition is efficacious in intracranial triple negative breast cancer models Cancer Research. 75: 2579-2579. DOI: 10.1158/1538-7445.Am2015-2579 |
0.468 |
|
| 2014 |
Seiser E, Gillis N, Parker J, Hayes DN, Eberhard D, Richards K, Auman JT, Innocenti F. 1614PPHARMACOGENETIC EVALUATION OF TARGETED DNA SEQUENCING IN CANCER PATIENTS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv558-iv559. PMID 28172051 DOI: 10.1093/Annonc/Mdu358.45 |
0.516 |
|
| 2014 |
Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nature Genetics. 46: 1051-9. PMID 25151356 DOI: 10.1038/Ng.3073 |
0.606 |
|
| 2014 |
Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. Journal of the National Cancer Institute. 106. PMID 25139534 DOI: 10.1093/Jnci/Dju152 |
0.649 |
|
| 2014 |
Orvis T, Hepperla A, Walter V, Song S, Simon J, Parker J, Wilkerson MD, Desai N, Major MB, Hayes DN, Davis IJ, Weissman B. BRG1/SMARCA4 inactivation promotes non-small cell lung cancer aggressiveness by altering chromatin organization. Cancer Research. 74: 6486-98. PMID 25115300 DOI: 10.1158/0008-5472.Can-14-0061 |
0.372 |
|
| 2014 |
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal of Cancer. 111: 1532-41. PMID 25101563 DOI: 10.1038/Bjc.2014.444 |
0.584 |
|
| 2014 |
Rathmell WK, Brooks SA, Parker JS, Nielsen ME. Reply to Alexander S. Parker, Brad C. Leibovich, Jeanette E. Eckel-Passow, John C. Cheville's letter to the editor re: Samira A. Brooks, A. Rose Brannon, Joel S. Parker, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol 2014;66:77-84. European Urology. 66: e92. PMID 25037640 DOI: 10.1016/J.Eururo.2014.07.002 |
0.334 |
|
| 2014 |
Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, ... ... Parker J, et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Research and Treatment. 146: 557-66. PMID 25001612 DOI: 10.1007/S10549-014-3039-Y |
0.597 |
|
| 2014 |
Wilkerson MD, Cabanski CR, Sun W, Hoadley KA, Walter V, Mose LE, Troester MA, Hammerman PS, Parker JS, Perou CM, Hayes DN. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Research. 42: e107. PMID 24970867 DOI: 10.1093/Nar/Gku489 |
0.662 |
|
| 2014 |
Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, Serody JS. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3818-29. PMID 24916698 DOI: 10.1158/1078-0432.Ccr-13-3368 |
0.723 |
|
| 2014 |
Mose LE, Wilkerson MD, Hayes DN, Perou CM, Parker JS. ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics (Oxford, England). 30: 2813-5. PMID 24907369 DOI: 10.1093/Bioinformatics/Btu376 |
0.411 |
|
| 2014 |
Zhao W, He X, Hoadley KA, Parker JS, Hayes DN, Perou CM. Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. Bmc Genomics. 15: 419. PMID 24888378 DOI: 10.1186/1471-2164-15-419 |
0.622 |
|
| 2014 |
Jeck WR, Parker J, Carson CC, Shields JM, Sambade MJ, Peters EC, Burd CE, Thomas NE, Chiang DY, Liu W, Eberhard DA, Ollila D, Grilley-Olson J, Moschos S, Neil Hayes D, et al. Targeted next generation sequencing identifies clinically actionable mutations in patients with melanoma. Pigment Cell & Melanoma Research. 27: 653-63. PMID 24628946 DOI: 10.1111/Pcmr.12238 |
0.398 |
|
| 2014 |
Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, Hakimi AA, Hsieh JJ, Choueiri TK, Tamboli P, Maranchie JK, Hinds P, Miller CR, Nielsen ME, Rathmell WK. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. European Urology. 66: 77-84. PMID 24613583 DOI: 10.1016/J.Eururo.2014.02.035 |
0.399 |
|
| 2014 |
Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS, Kim WY. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proceedings of the National Academy of Sciences of the United States of America. 111: 3110-5. PMID 24520177 DOI: 10.1073/Pnas.1318376111 |
0.672 |
|
| 2014 |
Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb JD, Rathmell WK, Davis IJ. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Research. 24: 241-50. PMID 24158655 DOI: 10.1101/Gr.158253.113 |
0.375 |
|
| 2014 |
Giannikopoulos P, St. John JA, Parker JS, Westesson O, Hahner NJ, Karachaliou N, Costa C, Caulin AF, Lozano MD, Perez-Gracia JL, Curioni Fontecedro A, Jantus-Lewintre E, Vergnenegre A, Gervais R, Bordoni R, et al. Integrated genomic analysis for revealing broad remodeling of EGFR-targeted therapy resistant lung cancers. Journal of Clinical Oncology. 32: 8083-8083. DOI: 10.1200/Jco.2014.32.15_Suppl.8083 |
0.318 |
|
| 2014 |
Giannikopoulos P, John JS, Hahner N, Parker JS, Karachaliou N, Costa C, Westesson O, Parikh U, Foo CK, Cauhlin AF, Lozano MD, Viteri S, Perez-Gracia JL, Curioni A, Jantus-Lewintre E, et al. Abstract 954: Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer patients with acquired resistance to erlotinib Cancer Research. 74: 954-954. DOI: 10.1158/1538-7445.Am2014-954 |
0.375 |
|
| 2014 |
Jo H, Patel NM, Weck KE, Eberhard DA, Hayes DN, Parker JS, Hayward M, Salazar A, Grilley-Olson JE. Abstract 5598: Correlating molecular and histopathologic tumor purity: An analysis of 816 patients Cancer Research. 74: 5598-5598. DOI: 10.1158/1538-7445.Am2014-5598 |
0.399 |
|
| 2014 |
Swearingen AEDV, Siegel MB, Bash R, Golitz B, Santos C, Darr D, Parker J, Johnson GL, Miller CR, Anders CK. Abstract 5449A: PI3K and MEK inhibition in intracranial triple negative breast cancer: Efficacy of BKM120 and AZD6244 in preclinical mouse models Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-5449A |
0.459 |
|
| 2013 |
Bardowell SA, Parker J, Fan C, Crandell J, Perou CM, Swift-Scanlan T. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Research and Treatment. 142: 365-80. PMID 24212716 DOI: 10.1007/S10549-013-2738-0 |
0.602 |
|
| 2013 |
Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, Perou CM. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Research and Treatment. 142: 237-55. PMID 24162158 DOI: 10.1158/1538-7445.Am2011-3328 |
0.586 |
|
| 2013 |
Roll JD, Rivenbark AG, Sandhu R, Parker JS, Jones WD, Carey LA, Livasy CA, Coleman WB. Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. Experimental and Molecular Pathology. 95: 276-87. PMID 24045095 DOI: 10.1016/J.Yexmp.2013.09.001 |
0.517 |
|
| 2013 |
Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, Arora VK, Yen WF, Cai L, Zheng D, Carver BS, Chen Y, Watson PA, Shah NP, Fujisawa S, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discovery. 3: 1245-53. PMID 24027196 DOI: 10.1158/2159-8290.Cd-13-0172 |
0.327 |
|
| 2013 |
King IF, Yandava CN, Mabb AM, Hsiao JS, Huang HS, Pearson BL, Calabrese JM, Starmer J, Parker JS, Magnuson T, Chamberlain SJ, Philpot BD, Zylka MJ. Topoisomerases facilitate transcription of long genes linked to autism. Nature. 501: 58-62. PMID 23995680 DOI: 10.1038/Nature12504 |
0.324 |
|
| 2013 |
Cabanski CR, Wilkerson MD, Soloway M, Parker JS, Liu J, Prins JF, Marron JS, Perou CM, Hayes DN. BlackOPs: increasing confidence in variant detection through mappability filtering. Nucleic Acids Research. 41: e178. PMID 23935067 DOI: 10.1093/Nar/Gkt692 |
0.47 |
|
| 2013 |
Cleary SP, Jeck WR, Zhao X, Chen K, Selitsky SR, Savich GL, Tan TX, Wu MC, Getz G, Lawrence MS, Parker JS, Li J, Powers S, Kim H, Fischer S, et al. Identification of driver genes in hepatocellular carcinoma by exome sequencing. Hepatology (Baltimore, Md.). 58: 1693-702. PMID 23728943 DOI: 10.1002/Hep.26540 |
0.316 |
|
| 2013 |
Zawistowski JS, Nakamura K, Parker JS, Granger DA, Golitz BT, Johnson GL. MicroRNA 9-3p targets β1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. Molecular and Cellular Biology. 33: 2260-74. PMID 23530058 DOI: 10.1128/Mcb.00269-13 |
0.354 |
|
| 2013 |
Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 203-9. PMID 23233704 DOI: 10.1200/Jco.2012.43.4134 |
0.642 |
|
| 2013 |
Rathmell K, Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Nielsen ME. A validated 34-gene signature for assessing risk of recurrence in clear cell renal cell carcinoma. Journal of Clinical Oncology. 31: 4522-4522. DOI: 10.1200/Jco.2013.31.15_Suppl.4522 |
0.306 |
|
| 2013 |
Hoadley KA, Fan C, Wilkerson MD, Mose LE, Jefferys SR, Auman JT, Parker JS, Hayes DN, Perou CM. Abstract SY12-03: Multi-tumor analysis of TCGA data identifies expression commonalities across tumor types. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy12-03 |
0.695 |
|
| 2013 |
Cleary SP, Jeck WR, Zhao X, Selitsky SR, Savich GL, Tan T, Wu MC, Getz G, Lawrence MS, Parker JS, Li J, Powers S, Kim H, Fischer SE, Guindi M, et al. Abstract 4598: Identification of driver genes in hepatocellular carcinoma by exome sequencing. Cancer Research. 73: 4598-4598. DOI: 10.1158/1538-7445.Am2013-4598 |
0.357 |
|
| 2012 |
Chao HH, He X, Parker JS, Zhao W, Perou CM. Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. Plos One. 7: e51719. PMID 23284754 DOI: 10.1371/Journal.Pone.0051719 |
0.736 |
|
| 2012 |
Cabanski CR, Cavin K, Bizon C, Wilkerson MD, Parker JS, Wilhelmsen KC, Perou CM, Marron JS, Hayes DN. ReQON: a Bioconductor package for recalibrating quality scores from next-generation sequencing data. Bmc Bioinformatics. 13: 221. PMID 22946927 DOI: 10.1186/1471-2105-13-221 |
0.427 |
|
| 2012 |
Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Research and Treatment. 135: 301-6. PMID 22752290 DOI: 10.1007/S10549-012-2143-0 |
0.617 |
|
| 2012 |
Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4465-72. PMID 22711706 DOI: 10.1158/1078-0432.Ccr-12-0286 |
0.592 |
|
| 2012 |
Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2866-73. PMID 22532584 DOI: 10.1200/Jco.2011.29.15_Suppl.502 |
0.616 |
|
| 2012 |
Dahlman KB, Parker JS, Shamu T, Hieronymus H, Chapinski C, Carver B, Chang K, Hannon GJ, Sawyers CL. Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening Plos One. 7. PMID 22509301 DOI: 10.1371/Journal.Pone.0034414 |
0.32 |
|
| 2012 |
Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2402-12. PMID 22351696 DOI: 10.1158/1078-0432.Ccr-11-2956 |
0.599 |
|
| 2012 |
Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Børresen-Dale AL, Olopade OI, Perou CM. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Research and Treatment. 133: 865-80. PMID 22048815 DOI: 10.1007/S10549-011-1846-Y |
0.75 |
|
| 2012 |
Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Research and Treatment. 132: 523-35. PMID 21671017 DOI: 10.1007/S10549-011-1619-7 |
0.565 |
|
| 2012 |
Prat A, Lluch A, Albanell J, Fang C, Lopez-Muniz JIC, Parker JS, Calvo L, Plazaola A, Lanza AA, Seguí-Palmer MA, Burgues O, Vicioso L, Sanchez-Simon R, Bermejo B, Ribelles N, et al. Gene expression-based predictors of chemotherapy response in basal-like breast cancer. Journal of Clinical Oncology. 30: 10500-10500. DOI: 10.1200/Jco.2012.30.15_Suppl.10500 |
0.619 |
|
| 2012 |
Smith MB, Earp HS, Parker JS, Caskey LS, Caudle AS, Calvo BF. Abstract 4527: The HER3-EREG axis and its role in colorectal cancer aggression Cancer Research. 72: 4527-4527. DOI: 10.1158/1538-7445.Am2012-4527 |
0.418 |
|
| 2012 |
Hoadley K, Parker J, Wilkerson, Mose L, Jefferys S, Soloway M, Turman Y, Auman J, Hayes D, Perou C. Abstract S6-1: Exploration of isoform switching and mutation expression in breast cancer by mRNA-sequencing analysis Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S6-1 |
0.67 |
|
| 2011 |
Holbrook JD, Parker JS, Gallagher KT, Halsey WS, Hughes AM, Weigman VJ, Lebowitz PF, Kumar R. Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. Journal of Translational Medicine. 9: 119. PMID 21781349 DOI: 10.1186/1479-5876-9-119 |
0.365 |
|
| 2011 |
Elloumi F, Hu Z, Li Y, Parker JS, Gulley ML, Amos KD, Troester MA. Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples. Bmc Medical Genomics. 4: 54. PMID 21718502 DOI: 10.1186/1755-8794-4-54 |
0.422 |
|
| 2011 |
Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2342-9. PMID 21555689 DOI: 10.1200/Jco.2010.31.6950 |
0.424 |
|
| 2011 |
Dunbier AK, Anderson H, Ghazoui Z, Salter J, Parker JS, Perou CM, Smith IE, Dowsett M. Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids. 76: 736-40. PMID 21447351 DOI: 10.1016/J.Steroids.2011.02.025 |
0.6 |
|
| 2011 |
Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R, Moonsamy P, Dahlman K, Miller VA, Costa C, Hannon G, Sawyers CL. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature. 471: 523-6. PMID 21430781 DOI: 10.1038/Nature09870 |
0.306 |
|
| 2011 |
Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, Perou CM. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. Bmc Medical Genomics. 4: 3. PMID 21214954 DOI: 10.1186/1755-8794-4-3 |
0.636 |
|
| 2011 |
Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N, Perou CM. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e18-20. PMID 21115855 DOI: 10.1200/Jco.2010.28.9199 |
0.526 |
|
| 2011 |
Chung CH, Pohlmann PR, Rothenberg ML, Burkey BB, Parker J, Palka K, Aulino J, Puzanov I, Murphy B. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma Head and Neck. 33: 1804-1808. PMID 20652976 DOI: 10.1002/Hed.21478 |
0.344 |
|
| 2011 |
Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM. Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer Breast Cancer Research. 13. DOI: 10.1186/bcr2909 |
0.694 |
|
| 2010 |
Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. Plos One. 5: e13073. PMID 20949095 DOI: 10.1371/Journal.Pone.0013073 |
0.795 |
|
| 2010 |
Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5222-32. PMID 20837693 DOI: 10.1158/1078-0432.Ccr-10-1282 |
0.622 |
|
| 2010 |
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research : Bcr. 12: R68. PMID 20813035 DOI: 10.1186/Bcr2635 |
0.802 |
|
| 2010 |
Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. The Lancet. Oncology. 11: 718-9; author reply . PMID 20688274 DOI: 10.1016/S1470-2045(10)70176-5 |
0.586 |
|
| 2010 |
Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, ... ... Parker J, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nature Biotechnology. 28: 827-38. PMID 20676074 DOI: 10.1038/Nbt.1665 |
0.364 |
|
| 2010 |
Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1161-7. PMID 20124184 DOI: 10.1200/Jco.2009.23.9616 |
0.584 |
|
| 2010 |
Haugen AC, Di Prospero NA, Parker JS, Fannin RD, Chou J, Meyer JN, Halweg C, Collins JB, Durr A, Fischbeck K, Van Houten B. Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathology. Plos Genetics. 6: e1000812. PMID 20090835 DOI: 10.1371/Journal.Pgen.1000812 |
0.336 |
|
| 2010 |
Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker JS, Swain SM, Hunter K, Zujewski JA. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer. Breast Cancer Research and Treatment. 119: 685-99. PMID 20012355 DOI: 10.1007/S10549-009-0651-3 |
0.456 |
|
| 2010 |
Sandhu R, Parker JS, Jones WD, Livasy CA, Coleman WB. Microarray-based gene expression profiling for molecular classification of breast cancer and identification of new targets for therapy Laboratory Medicine. 41: 364-372. DOI: 10.1309/Lmlik0Vie3Cjk0Wd |
0.509 |
|
| 2010 |
Ellis M, Suman V, Hoog J, Lin L, Snider J, Parker J, Deshryver K, Watson M, Allred C, Hunt K, Olson J. Abstract S1-2: ACOSOG Z1031: A Randomized Neoadjuvant Comparison between Letrozole (LET), Anastrozole (ANA) and Exemestane (EXE) for Postmenopausal Women with ER Rich Stage 2/3 Breast Cancer: Biomarker Outcomes and the Predictive Value of the Baseline PAM50 Based Intrinsic Subtype Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-S1-2 |
0.389 |
|
| 2009 |
Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Research : Bcr. 11: R55. PMID 19638211 DOI: 10.1186/Bcr2344 |
0.742 |
|
| 2009 |
Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, Aakre M, Shyr Y, Moses HL. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. The Journal of Clinical Investigation. 119: 1571-82. PMID 19451693 DOI: 10.1172/Jci37480 |
0.421 |
|
| 2009 |
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute. 101: 736-50. PMID 19436038 DOI: 10.1093/Jnci/Djp082 |
0.639 |
|
| 2009 |
Crowder RJ, Phommaly C, Tao Y, Hoog J, Luo J, Perou CM, Parker JS, Miller MA, Huntsman DG, Lin L, Snider J, Davies SR, Olson JA, Watson MA, Saporita A, et al. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Research. 69: 3955-62. PMID 19366795 DOI: 10.1158/0008-5472.Can-08-4450 |
0.596 |
|
| 2009 |
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1160-7. PMID 19204204 DOI: 10.1200/Jco.2008.18.1370 |
0.62 |
|
| 2009 |
Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR. A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Research. 69: 65-74. PMID 19117988 DOI: 10.1158/0008-5472.Can-08-0377 |
0.33 |
|
| 2009 |
Thorner AR, Hoadley KA, Parker JS, Winkel S, Millikan RC, Perou CM. In vitro and in vivo analysis of B-Myb in basal-like breast cancer. Oncogene. 28: 742-51. PMID 19043454 DOI: 10.1038/Onc.2008.430 |
0.8 |
|
| 2009 |
Harris LN, Parker J, Broadwater G, Schulz V, Halligan K, Geyda K, Seidman A, Berry D, Winer E, Hudis C, Krasnitz A, Hicks J, Tuck DP, Perou C. Genome-Wide Profiling of Archived Material from CALGB 9840 and 9342 for Paclitaxel (P) and Trastuzumab (T) Response Biomarkers Using Gene Expression and Copy Number Analysis. Cancer Research. 69: 4032-4032. DOI: 10.1158/0008-5472.Sabcs-09-4032 |
0.59 |
|
| 2009 |
Parker J, Prat A, Cheang M, Lenburg M, Paik S, Perou C. Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy. Cancer Research. 69: 2019-2019. DOI: 10.1158/0008-5472.Sabcs-09-2019 |
0.614 |
|
| 2009 |
Liu X, Parker J, Fan C, Perou CM, Marron JS. Visualization of Cross-Platform Microarray Normalization Batch Effects and Noise in Microarray Experiments: Sources and Solutions. 167-181. DOI: 10.1002/9780470685983.ch14 |
0.381 |
|
| 2008 |
Parker J, Mullins M, Cheang MC, Davies S, Mardis E, Nielsen TO, Ellis MJ, Marron S, Perou CM, Bernard PS. A supervised risk predictor of breast cancer based on biological subtypes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 11008. PMID 27948334 DOI: 10.1200/Jco.2008.26.15_Suppl.11008 |
0.549 |
|
| 2008 |
Charles PC, Alder BD, Hilliard EG, Schisler JC, Lineberger RE, Parker JS, Mapara S, Wu SS, Portbury A, Patterson C, Stouffer GA. Tobacco use induces anti-apoptotic, proliferative patterns of gene expression in circulating leukocytes of Caucasian males. Bmc Medical Genomics. 1: 38. PMID 18710571 DOI: 10.1186/1755-8794-1-38 |
0.322 |
|
| 2008 |
Wakamatsu N, Collins JB, Parker JS, Tessema M, Clayton NP, Ton TV, Hong HH, Belinsky S, Devereux TR, Sills RC, Lahousse SA. Gene expression studies demonstrate that the K-ras/Erk MAP kinase signal transduction pathway and other novel pathways contribute to the pathogenesis of cumene-induced lung tumors. Toxicologic Pathology. 36: 743-52. PMID 18648096 DOI: 10.1177/0192623308320801 |
0.32 |
|
| 2008 |
Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Molecular and Cellular Biology. 28: 5605-20. PMID 18625725 DOI: 10.1128/Mcb.00787-08 |
0.373 |
|
| 2008 |
Gohlke JM, Armant O, Parham FM, Smith MV, Zimmer C, Castro DS, Nguyen L, Parker JS, Gradwohl G, Portier CJ, Guillemot F. Characterization of the proneural gene regulatory network during mouse telencephalon development. Bmc Biology. 6: 15. PMID 18377642 DOI: 10.1186/1741-7007-6-15 |
0.319 |
|
| 2008 |
Silva JM, Marran K, Parker JS, Silva J, Golding M, Schlabach MR, Elledge SJ, Hannon GJ, Chang K. Profiling essential genes in human mammary cells by multiplex RNAi screening Science. 319: 617-620. PMID 18239125 DOI: 10.1126/Science.1149185 |
0.344 |
|
| 2007 |
Muse GW, Gilchrist DA, Nechaev S, Shah R, Parker JS, Grissom SF, Zeitlinger J, Adelman K. RNA polymerase is poised for activation across the genome. Nature Genetics. 39: 1507-11. PMID 17994021 DOI: 10.1038/Ng.2007.21 |
0.32 |
|
| 2007 |
Mullins M, Perreard L, Quackenbush JF, Gauthier N, Bayer S, Ellis M, Parker J, Perou CM, Szabo A, Bernard PS. Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clinical Chemistry. 53: 1273-9. PMID 17525107 DOI: 10.1373/Clinchem.2006.083725 |
0.601 |
|
| 2006 |
Chung CH, Parker JS, Ely K, Carter J, Yi Y, Murphy BA, Ang KK, El-Naggar AK, Zanation AM, Cmelak AJ, Levy S, Slebos RJ, Yarbrough WG. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Research. 66: 8210-8. PMID 16912200 DOI: 10.1158/0008-5472.Can-06-1213 |
0.396 |
|
| 2006 |
Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, Livasy C, Carey LA, Reynolds E, Dressler L, Nobel A, Parker J, Ewend MG, Sawyer LR, Wu J, et al. The molecular portraits of breast tumors are conserved across microarray platforms. Bmc Genomics. 7: 96. PMID 16643655 DOI: 10.1186/1471-2164-7-96 |
0.738 |
|
| 2006 |
Perreard L, Fan C, Quackenbush JF, Mullins M, Gauthier NP, Nelson E, Mone M, Hansen H, Buys SS, Rasmussen K, Orrico AR, Dreher D, Walters R, Parker J, Hu Z, et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Research : Bcr. 8: R23. PMID 16626501 DOI: 10.1186/Bcr1399 |
0.566 |
|
| 2005 |
Malarkey DE, Parker JS, Turman CA, Scott AM, Paules RS, Collins J, Maronpot RR. Microarray data analysis of mouse neoplasia. Toxicologic Pathology. 33: 127-35. PMID 15805064 DOI: 10.1080/01926230590888315 |
0.413 |
|
| 2004 |
Thomson JM, Parker J, Perou CM, Hammond SM. A custom microarray platform for analysis of microRNA gene expression Nat Methods. 1: 47-53. PMID 15782152 DOI: 10.1038/Nmeth704 |
0.489 |
|
| 2004 |
Troester MA, Hoadley KA, Parker JS, Perou CM. Prediction of toxicant-specific gene expression signatures after chemotherapeutic treatment of breast cell lines. Environmental Health Perspectives. 112: 1607-13. PMID 15598611 DOI: 10.1289/Txg.7204 |
0.672 |
|
| 2004 |
Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC, Dressler LG, Shores CG, Yarbrough WG, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 5: 489-500. PMID 15144956 DOI: 10.1016/S1535-6108(04)00112-6 |
0.524 |
|
| 2004 |
Benito M, Parker J, Du Q, Wu J, Xiang D, Perou CM, Marron JS. Adjustment of systematic microarray data biases. Bioinformatics (Oxford, England). 20: 105-14. PMID 14693816 DOI: 10.1093/Bioinformatics/Btg385 |
0.452 |
|
| 2003 |
Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lønning PE, Brown PO, Børresen-Dale AL, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 100: 8418-23. PMID 12829800 DOI: 10.1073/Pnas.0932692100 |
0.632 |
|
| Show low-probability matches. |